File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Screening for hepatocellular carcinoma: Survival benefit and cost-effectiveness

TitleScreening for hepatocellular carcinoma: Survival benefit and cost-effectiveness
Authors
Issue Date2003
PublisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/
Citation
Annals Of Oncology, 2003, v. 14 n. 10, p. 1463-1467 How to Cite?
AbstractBackground: The prognosis for patients with hepatocellular carcinoma (HCC) is poor by the time they present with symptoms. This review examines the usefulness of screening programs from the perspectives of survival benefit and of cost-effectiveness. Materials and methods: Articles were searched through Medline for screening, HCC, treatment and cost-effectiveness. Results: Both ultrasonography and α-fetoprotein testing have a low sensitivity for detecting HCC, although a combination of the two investigations can increase sensitivity. They remain the main screening methods because they are convenient, non-invasive and easily assessable. Though earlier studies fail to show improvement in patient management and survival by screening, more recent studies demonstrate that screening can increase the chance of curative treatment and, more importantly, improve survival even after the adjustment of lead-time bias. This is probably due to the improvement in medical treatment and technology. The cost per tumor detected for a region is inversely proportional to the tumor incidence of that region. Conclusions: In countries with a low prevalence of HCC, screening for HCC is not cost-effective. But in countries with a high prevalence of HCC, especially when screening is directed at older patients with a high risk of HCC, screening programs for HCC become much more cost-effective.
Persistent Identifierhttp://hdl.handle.net/10722/77742
ISSN
2015 Impact Factor: 9.269
2015 SCImago Journal Rankings: 4.362
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorYuen, MFen_HK
dc.contributor.authorLai, CLen_HK
dc.date.accessioned2010-09-06T07:35:14Z-
dc.date.available2010-09-06T07:35:14Z-
dc.date.issued2003en_HK
dc.identifier.citationAnnals Of Oncology, 2003, v. 14 n. 10, p. 1463-1467en_HK
dc.identifier.issn0923-7534en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77742-
dc.description.abstractBackground: The prognosis for patients with hepatocellular carcinoma (HCC) is poor by the time they present with symptoms. This review examines the usefulness of screening programs from the perspectives of survival benefit and of cost-effectiveness. Materials and methods: Articles were searched through Medline for screening, HCC, treatment and cost-effectiveness. Results: Both ultrasonography and α-fetoprotein testing have a low sensitivity for detecting HCC, although a combination of the two investigations can increase sensitivity. They remain the main screening methods because they are convenient, non-invasive and easily assessable. Though earlier studies fail to show improvement in patient management and survival by screening, more recent studies demonstrate that screening can increase the chance of curative treatment and, more importantly, improve survival even after the adjustment of lead-time bias. This is probably due to the improvement in medical treatment and technology. The cost per tumor detected for a region is inversely proportional to the tumor incidence of that region. Conclusions: In countries with a low prevalence of HCC, screening for HCC is not cost-effective. But in countries with a high prevalence of HCC, especially when screening is directed at older patients with a high risk of HCC, screening programs for HCC become much more cost-effective.en_HK
dc.languageengen_HK
dc.publisherOxford University Press. The Journal's web site is located at http://annonc.oxfordjournals.org/en_HK
dc.relation.ispartofAnnals of Oncologyen_HK
dc.rightsAnnals of Oncology. Copyright © Oxford University Press.en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAge Factorsen_HK
dc.subject.meshAgeden_HK
dc.subject.meshCarcinoma, Hepatocellular - diagnosis - economics - pathologyen_HK
dc.subject.meshCost-Benefit Analysisen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLiver Neoplasms - diagnosis - economics - pathologyen_HK
dc.subject.meshMass Screeningen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshSensitivity and Specificityen_HK
dc.subject.meshSurvival Analysisen_HK
dc.subject.meshUltrasonography - economicsen_HK
dc.subject.meshalpha-Fetoproteins - analysisen_HK
dc.titleScreening for hepatocellular carcinoma: Survival benefit and cost-effectivenessen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0923-7534&volume=14&spage=1463&epage=1467&date=2003&atitle=Screening+For+Hepatocellular+Carcinoma:+Survival+Benefit+And+Cost-effectivenessen_HK
dc.identifier.emailYuen, MF:mfyuen@hkucc.hku.hken_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityYuen, MF=rp00479en_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/annonc/mdg400en_HK
dc.identifier.pmid14504044-
dc.identifier.scopuseid_2-s2.0-0142248269en_HK
dc.identifier.hkuros87528en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0142248269&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume14en_HK
dc.identifier.issue10en_HK
dc.identifier.spage1463en_HK
dc.identifier.epage1467en_HK
dc.identifier.isiWOS:000186040900003-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridYuen, MF=7102031955en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats